-
Countdown to ILCSC24: Bringing the World’s Experts Right to Your Living Room
Read time: 3 minutes.
One of LUNGevity’s two flagship survivorship events, the International Lung Cancer Survivorship Conference (ILCSC), is being held virtually September 20 – 21, 2024. This is a...
IN THE SPOTLIGHT
-
How Can Patients and Researchers Design Clinical Trials Together?
Read time: 2 minutes. Traditionally, people associate getting involved in lung cancer research with enrolling in a clinical trial. But most don’t realize they can also partner with... -
2024 ASCO: Highlights of Lung Cancer Research
Read time: 8 minutes Thousands of oncologists, scientists, biotech and pharmaceutical representatives, patients, and advocates (including LUNGevity staff) met to discuss lifesaving... -
Is Lung Cancer in Young Adults Hereditary?
Read time: 2 minutes The question of whether lung cancer is hereditary is becoming increasingly important in the lung cancer community. While the average age of lung cancer... -
Frank Sierawski: A New Meaning for Father’s Day
Read time: 3 minutes It’s been nearly a decade since Frank Sierawski was diagnosed with stage IV lung cancer in his 30s. The Sierawski family—including Frank, his wife Kathryn, and... -
Researcher Aims to Bring 360-Degree Care to Young Adults Living with Lung Cancer
Young adults (less than 50 years of age) are being diagnosed with lung cancer at increasing rates. They tend to be women of Hispanic or Asian descent and are typically diagnosed... -
Safely Bring Yoga, Dietary Supplements, Exercise, and More into Your Lung Cancer Journey
Read time: 2 minutes Integrative oncology adds holistic approaches—such as acupuncture, nutrition, exercise, and mindfulness—into a treatment plan. Research shows these... -
Advice and Insights from Author and Two-Time Cancer Survivor Kathy Giusti
Kathy Giusti joined LUNGevity for a special conversation about her life as a cancer patient, caregiver, and the founder and former CEO of the Multiple Myeloma Research Foundation... -
Highlights of AACR 2024: Where the Laboratory Meets the Patient
Read time: 7 minutes It’s spring! The daffodils bloom, the days become longer, and I attend the annual meeting of the American Association for Cancer Research (AACR). For those of... -
ALK Virtual Meetup
ALK patients/survivors - Join us the 4th Wednesday of every month to connect with others who share common experiences and build your community.
Twenty Lung Cancer Advocacy Organizations and 23andMe Come Together to Launch Lung Cancer Genetics Study to Help Advance Research
Twenty Lung Cancer Advocacy Organizations and 23andMe Come Together to Launch Lung Cancer Genetics Study to Help Advance Research
Countdown to ILCSC24: Bringing the World’s Experts Right to Your Living Room
Countdown to ILCSC24: Bringing the World’s Experts Right to Your Living Room
Read time: 3 minutes. One of LUNGevity’s two flagship survivorship events, the International Lung Cancer Survivorship Conference (ILCSC), is being held virtually September 20 – 21, 2024. This is a free, online event that allows people with lung cancer and caregivers from around the world to join from the comfort of their own homes and hear from a star-studded lineup of lung cancer experts discussing the latest advances in research and treatment. You can register today for…
FDA approves Roche’s Alecensa as the first adjuvant treatment for people with ALK-positive early-stage lung cancer
FDA approves Roche’s Alecensa as the first adjuvant treatment for people with ALK-positive early-stage lung cancer
Nuvalent To Present Updated Data For ROS1-Selective Inhibitor, Zidesamtinib, And ALK-Selective Inhibitor, NVL-655, At The ESMO Congress 2024
Nuvalent To Present Updated Data For ROS1-Selective Inhibitor, Zidesamtinib, And ALK-Selective Inhibitor, NVL-655, At The ESMO Congress 2024
Practice Updates in Lung Cancer Stem From Biomarker Testing and Up-Front Immunotherapy
Key Data Updates From ASCO May Advance the Treatment Landscapes of 3 Lung Cancer Subtypes
Key Data Updates From ASCO May Advance the Treatment Landscapes of 3 Lung Cancer Subtypes
How Can Patients and Researchers Design Clinical Trials Together?
How Can Patients and Researchers Design Clinical Trials Together?
Read time: 2 minutes. Traditionally, people associate getting involved in lung cancer research with enrolling in a clinical trial. But most don’t realize they can also partner with researchers behind the scenes and get involved in designing clinical trials. In the first of a three-part series, Rising Tide Foundation for Clinical Cancer Research has partnered with LUNGevity to understand the role people with lung cancer can play in developing clinical trials. Through panelist…
Lung Cancer Expert at ASCO: From Fatal to 'Chronic Disease'
2024 ASCO: Highlights of Lung Cancer Research
2024 ASCO: Highlights of Lung Cancer Research
Read time: 8 minutesThousands of oncologists, scientists, biotech and pharmaceutical representatives, patients, and advocates (including LUNGevity staff) met to discuss lifesaving cancer research at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago from May 31 through June 4, 2024. The theme for this year’s conference, “The Art and Science of Cancer Care: From Comfort to Cure,” highlighted the importance of using both our creativity and our scientific…
Is Lung Cancer in Young Adults Hereditary?
Is Lung Cancer in Young Adults Hereditary?
Read time: 2 minutesThe question of whether lung cancer is hereditary is becoming increasingly important in the lung cancer community. While the average age of lung cancer diagnosis is approximately 70 years old, we are now seeing young adults in their 20s and 30s getting lung cancer.We currently suspect lung cancer in young adults may be caused by environmental factors (such as air pollution or chemical exposure), their genetic make-up, or some combination of these factors.We cannot say for…
Lung Cancer Was a Death Sentence. Now Drugs Are Saving Lives.
Frank Sierawski: A New Meaning for Father’s Day
Frank Sierawski: A New Meaning for Father’s Day
Read time: 3 minutesIt’s been nearly a decade since Frank Sierawski was diagnosed with stage IV lung cancer in his 30s. The Sierawski family—including Frank, his wife Kathryn, and their three kids—all experienced his diagnosis, treatment, and remission in different ways.“My kids have the luxury of not really remembering much of my treatments, surgery, brain radiation, etc. But my wife does. She remembers it like it was yesterday, and that's really given her some PTSD. You can imagine working…
Researcher Aims to Bring 360-Degree Care to Young Adults Living with Lung Cancer
Researcher Aims to Bring 360-Degree Care to Young Adults Living with Lung Cancer
Young adults (less than 50 years of age) are being diagnosed with lung cancer at increasing rates. They tend to be women of Hispanic or Asian descent and are typically diagnosed with advanced-stage lung cancer. Research is ongoing to help us develop effective options to treat these patients medically, but little is known about the effects of the diagnosis on their mental, social, and financial health or their family planning. To help us better understand the needs of this growing…
Lung Cancer Was a Death Sentence. Now Drugs Are Saving Lives.
Lorbrena Yields “Unprecedented” Progression-Free Survival for ALK-Positive Lung Cancer
'Outstanding' 5 Year Progression-Free Survival With Lorlatinib in ALK+ NSCLC
ASCO 2024: New study details longest progression-free survival ever reported in advanced NSCLC
ASCO 2024: New study details longest progression-free survival ever reported in advanced NSCLC
Advice and Insights from Author and Two-Time Cancer Survivor Kathy Giusti
Advice and Insights from Author and Two-Time Cancer Survivor Kathy Giusti
Kathy Giusti joined LUNGevity for a special conversation about her life as a cancer patient, caregiver, and the founder and former CEO of the Multiple Myeloma Research Foundation. Her involvement with the medical system from these different perspectives inspired her to write her recent book, Fatal to Fearless: 12 Steps to Beating Cancer in a Broken Medical System. You can watch the full 40-minute conversation with Kathy or use the timestamps below to learn more about the topics and advice…
NVL-655 Receives FDA Breakthrough Therapy Designation in ALK+ NSCLC
Safely Bring Yoga, Dietary Supplements, Exercise, and More into Your Lung Cancer Journey
Safely Bring Yoga, Dietary Supplements, Exercise, and More into Your Lung Cancer Journey
Read time: 2 minutesIntegrative oncology adds holistic approaches—such as acupuncture, nutrition, exercise, and mindfulness—into a treatment plan. Research shows these interventions can have a tremendous impact on people going through lung cancer treatment and their quality of life. Unfortunately, they are also topics riddled with myths and falsehoods. LUNGevity spoke to an expert to help sort out the facts from the fiction. In the webinar below, Gabriel Lopez, MD, medical director of…
Highlights of AACR 2024: Where the Laboratory Meets the Patient
Highlights of AACR 2024: Where the Laboratory Meets the Patient
Read time: 7 minutesIt’s spring! The daffodils bloom, the days become longer, and I attend the annual meeting of the American Association for Cancer Research (AACR). For those of you who are new to this meeting, it is the largest gathering of laboratory scientists and clinicians in the world—coming together to discuss how to take science from the bench (laboratory) to patients and communities. This year’s meeting was held in sunny San Diego and brought together more than 23,000 attendees. Below…
New Treatment Approved for Early-Stage ALK+ Lung Cancer
New Treatment Approved for Early-Stage ALK+ Lung Cancer
On April 18, 2024, the US Food and Drug Administration (FDA) announced the approval of alectinib to treat patients after surgical removal of ALK-positive non-small cell lung cancer (NSCLC).The approval is supported by data from the phase 3 ALINA trial, which showed that treating patients with alectinib reduced the risk of disease recurrence by 76% compared to treating them with chemotherapy.Alectinib is approved for use in patients with completely resected stage IB to IIIA ALK-positive NSCLC…
Alectinib Lands FDA Approval for Adjuvant Therapy in NSCLC
FDA approves Alecensa for certain patients with ALK-positive lung cancer
FDA Approves Alectinib to Treat Patients With ALK-Positive NSCLC
Chemo Shortage Didn’t Materialize ‘The Way We Initially Feared’
Chemo Shortage Didn’t Materialize ‘The Way We Initially Feared’
This March, LUNGevity Foundation partnered with CURE for their “Speaking Out” video series, inviting Amy Moore, PhD, vice president of global engagement and patient partnerships at LUNGevity Foundation, to discuss recent chemotherapy shortages. During the interview, Dr. Moore addressed the critical issues posed by the chemotherapy shortage, offering valuable insights into its origins, impact on people with lung cancer, available alternatives, and ongoing efforts to address disparities. Her…
Alectinib in Resected ALK-Positive Non-Small-Cell Lung Cancer
Treating Women With Lung Cancer: Screening, Treatment, and Sexual and Reproductive Health
Treating Women With Lung Cancer: Screening, Treatment, and Sexual and Reproductive Health
Caregivers: Planning the Self-Care Journey
Caregivers: Planning the Self-Care Journey
This webinar explains the phases of the caregiving cycle and offers tips and strategies for meeting the challenges of each phase. The discussion features Michelle Bolden, founder and chief education officer for Call For Caring Inc., a nonprofit organization educating and uplifting family caregivers in Atlanta. Michelle also hosts two podcasts -- "Call For Caring on Purpose" and "The Empowerment Hour." The webinar was recorded on March 7, 2024, as a Facebook Live event. It is hosted…
Cancer Grand Challenges Summit 2024: No Time to Waste in Addressing Some of Toughest Challenges in Cancer
Cancer Grand Challenges Summit 2024: No Time to Waste in Addressing Some of Toughest Challenges in Cancer
Read time: 4 minutesI just returned from the Cancer Grand Challenges Summit, held March 5–8, 2024 in London, England. Cancer Grand Challenges was launched in 2020 as a collaboration between Cancer Research UK and the National Cancer Institute in the US, whereby they provide $25 million to international, multi-institutional teams working to address some of the most perplexing issues in the cancer field. I am LUNGevity’s representative on Team CANCAN, which is working to understand and treat…